BS EN ISO 10993-5-2009 + A11-2025 PDF

Full title and description

BS EN ISO 10993-5:2009 + A11:2025 — Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity. This entry describes the British/European adoption of ISO 10993‑5:2009 amended by Amendment A11 (2025), which updates the normative annexes and the European foreword to clarify the relationship of in vitro cytotoxicity testing to regulatory conformity assessment.

Abstract

This amendment (A11:2025) to EN/ISO 10993‑5:2009 provides clarifications and additions to the existing test methods for assessing in vitro cytotoxicity of medical device materials and extracts. The document specifies commonly used approaches (direct contact, indirect contact/extracts and diffusion methods), controls and acceptance criteria, and how results should be interpreted and reported as part of a device’s biological evaluation. The amendment also aligns the European implementation text (Annex ZA) with current regulatory expectations.

General information

• Status: Published / Current (definitive text made available as an EN/BS adoption of ISO 10993‑5 with Amendment A11:2025).
• Publication date: March 2025 (BS EN national publication noted 17 March 2025 for the British adoption; other national adoptions record March–May 2025 effective dates).
• Publisher: BSI as the British adoption of EN ISO 10993‑5:2009 with Amendment A11:2025 (CEN/ISO origin).
• ICS / categories: 11.100.20 — Biological evaluation of medical devices; laboratory medicine/biocompatibility testing.
• Edition / version: ISO 10993‑5:2009 with Amendment A11:2025 (EN/BS adoption designated BS EN ISO 10993‑5:2009 + A11:2025).
• Number of pages: Amendment document typically short (national listings show the A11 amendment as roughly 6–11 pages; full Part 5 original text is considerably longer).

Summary details above draw on national and CEN/ISO publication records for the EN/BS adoption (March–May 2025).

Scope

The standard (Part 5) specifies in vitro cytotoxicity test methods to evaluate the potential of medical device materials, extracts, residues or degradation products to produce a cytotoxic effect on mammalian cells. It gives procedures for sample preparation (extracts), choice of cell systems, exposure methods (direct contact, indirect contact, diffusion), control requirements, test performance and interpretation of results. The amendment A11 clarifies the application of these methods within the European regulatory framework and the role of the tests in conformity assessment.

Key topics and requirements

• Defined test methods: direct contact, indirect contact (extract/eluate testing), and diffusion methods.
• Selection of appropriate cell lines and culture conditions to detect cytotoxic responses.
• Preparation of extracts (solvent selection, surface‑area/volume ratio, extraction conditions) and guidance on sample types.
• Mandatory positive and negative controls and acceptance criteria for test validity.
• Qualitative and quantitative evaluation/scoring of cytotoxic effects (morphology, viability assays, assay-specific endpoints).
• Requirements for reporting results, interpretation in the context of risk management, and linkage to chemical characterisation/sample information.
• Annex/foreword adjustments to align the test role with European conformity and the MDR/medical-device regulatory framework.

These topics reflect the amendment’s emphasis on test selection, validity and regulatory alignment.

Typical use and users

Used by medical device manufacturers, contract testing laboratories, notified bodies, regulatory reviewers and research groups involved in biocompatibility assessment. Typical applications include pre‑clinical evaluation of materials, batch or process change assessments, and generation of data for technical files and regulatory submissions. Laboratories use the methods to screen materials and extracts for cytotoxic potential as part of a broader biological evaluation strategy.

Related standards

ISO 10993 series (notably ISO 10993‑1 — evaluation and testing within a risk management framework; ISO 10993‑12 — sample preparation and reference materials; ISO 10993‑18 — chemical characterisation and biological evaluation; ISO 10993‑10 — irritation and skin sensitization; ISO 10993‑17 — toxicokinetics/toxicological risk assessment). National/adopted EN versions and relevant Annex ZA text link the part to European regulatory requirements.

Keywords

in vitro cytotoxicity, biological evaluation, medical devices, ISO 10993‑5, amendment A11, extract testing, direct contact, cell culture, biocompatibility, Annex ZA, MDR alignment

FAQ

Q: What is this standard?

A: It is the EN/BS adoption of ISO 10993‑5:2009 (Part 5 of the ISO 10993 biological evaluation series) amended by Amendment A11 issued in 2025; it specifies in vitro cytotoxicity test methods for medical-device materials.

Q: What does it cover?

A: It covers procedures for direct-contact, indirect-contact (extract/eluate) and diffusion cytotoxicity tests, control requirements, evaluation/acceptance criteria and reporting — and, via the amendment, clarifies the European implementation and regulatory relevance.

Q: Who typically uses it?

A: Medical device manufacturers, contract testing laboratories, notified bodies and regulatory assessors use it when generating or reviewing cytotoxicity data for technical files and conformity assessments.

Q: Is it current or superseded?

A: The base ISO 10993‑5:2009 remains the underlying technical text; Amendment A11:2025 is a current, published European/BS amendment to that text (published nationally in March–May 2025). Users should confirm they are using the ISO text together with the A11 amendment as adopted in their jurisdiction.

Q: Is it part of a series?

A: Yes — it is Part 5 of the ISO 10993 series on biological evaluation of medical devices; compliance and interpretation are intended to be considered alongside other parts (e.g., Parts 1, 10, 12, 17, 18).

Q: What are the key keywords?

A: in vitro cytotoxicity, extract testing, direct contact, biocompatibility, ISO 10993, amendment A11, Annex ZA, medical device testing.